Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | -2M | -2M | 0 | 0 |
| Operating Income | -51M | -67M | -81M | -80M | -38M |
| EBITDA | -50M | -61M | -69M | 6M | -35M |
| Net Income | -50M | -63M | -71M | 5M | -35M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.23
-2.54% today
1Y Change
-96.82%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vicarious Surgical Inc. (RBOT) is a Healthcare stock with listed on OTC. The stock last traded around $0.23 and down 96.8% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +21.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +21.2%, free cash flow +9.8% with operating margin 0.0% and ROIC -411.0%. Stock Foundry combines RBOT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RBOT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RBOT Max Drawdown
-98.10%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RBOT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$35.2M
-782.7% YoY
Free Cash Flow
-$34.6M
+48.0% YoY
Revenue Growth
+0.0%
EPS Growth
+21.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | -2M | -2M | 0 | 0 |
| Operating Income | -51M | -67M | -81M | -80M | -38M |
| EBITDA | -50M | -61M | -69M | 6M | -35M |
| Net Income | -50M | -63M | -71M | 5M | -35M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 10M | 53M | 116M | 174M |
| Total Assets | 20M | 68M | 120M | 140M | 182M |
| Total Liabilities | 10M | 21M | 22M | 29M | 99M |
| Shareholder Equity | 10M | 47M | 98M | 111M | 83M |
| Total Debt | 8M | 14M | 15M | 16M | 1M |
| Net Debt | 5M | 4M | -38M | -101M | -172M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
33M
+45.6% YoY
Capital Expenditures
1M
+75.9% YoY
Free Cash Flow
35M
+48.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-333.2%
Debt / Equity
1.91x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.